UB Paderborn / Katalog / Suche / in CDI

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

European urology, 2009-06, Vol.55 (6), p.1269-1277

2009

Volltextzugriff (PDF)

GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors

Endocrine, 2009-08, Vol.36 (1), p.87-97

2009

Volltextzugriff (PDF)

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

Urology, 2005-12, Vol.66 (6), p.35-63

2005

Volltextzugriff (PDF)

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

European urology, 2003-10, Vol.44 (4), p.429-434

2003

Volltextzugriff (PDF)

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

Cellular Oncology, 2011-06, Vol.34 (3), p.235-243

2011

Volltextzugriff (PDF)

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

Urology, 2005-12, Vol.66 (6), p.64-74

2005

Volltextzugriff (PDF)

Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction

Cellular oncology : the official journal of the International Society for Cellular Oncology, 2008, Vol.30 (6), p.473-482

2008

Volltextzugriff (PDF)

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

Analytical cellular pathology (Amsterdam), 2010-01, Vol.33 (1), p.27-36

2010

Volltextzugriff (PDF)

Handling and Pathology Reporting of Radical Prostatectomy Specimens

European urology, 2003-12, Vol.44 (6), p.626-636

2003

Volltextzugriff (PDF)

Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer

BJU international, 2010-10, Vol.106 (7), p.1072-1080

2010

Volltextzugriff (PDF)

The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

European urology, 2003-10, Vol.44 (4), p.423-428

2003

Volltextzugriff (PDF)

Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma

Asian journal of andrology, 2011-03, Vol.13 (2), p.242-247

2011

Volltextzugriff (PDF)

Histopathology reporting of prostate needle biopsies. 2005 update

Virchows Archiv : an international journal of pathology, 2006-07, Vol.449 (1), p.1-13

2006

Volltextzugriff (PDF)

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

European urology, 2022-01, Vol.81 (1), p.50-61

2022

Volltextzugriff (PDF)

Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months

Journal of clinical pathology, 2007-04, Vol.60 (4), p.443-446

2007

Volltextzugriff (PDF)

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

The lancet oncology, 2015-01, Vol.16 (1), p.76-86

2015

Volltextzugriff (PDF)

Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis

Analytical and quantitative cytology and histology, 2010-06, Vol.32 (3), p.136

2010

Volltextzugriff (PDF)

Gene expression profiling of renal cell carcinoma: a DNA macroarray analysis

BJU international, 2006-07, Vol.98 (1), p.205-216

2006

Volltextzugriff (PDF)

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

Analytical cellular pathology (Amsterdam), 2010, Vol.33 (1), p.27-36

2010

Volltextzugriff (PDF)

The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use

Clinical therapeutics, 2005-03, Vol.27 (3), p.273-285

2005

Volltextzugriff (PDF)

Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study

Urology (Ridgewood, N.J.), 2001, Vol.57 (1), p.117-121

2001

Volltextzugriff (PDF)

Maintenance Bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a european organisation for research and treatment of cancer genito-urinary group phase III trial

European urology, 2003-10, Vol.44 (4), p.429-434

2003

Volltextzugriff (PDF)

Surgical pathology examination of radical prostatectomy specimens. Updated protocol based on the Italian TAP study

Anticancer research, 2001-09, Vol.21 (5), p.3599

2001

Volltextzugriff (PDF)

Somatostatin receptor subtypes in hormone-refractory （castration-resistant） prostatic carcinoma

Asian journal of andrology, 2011, Vol.13 (2), p.242-247

Roberta Mazzucchelli Doriana Morichetti Marina Scarpelli Aldo V Bono Antonio Lopez-Beltran Liang Cheng Ziya Kirkali Rodolfo Montironi

2011

Volltextzugriff (PDF)

Overview of Current Treatment Strategies in Prostate Cancer

European urology supplements : official journal of the European Association of Urology, 2004-02, Vol.3 (1), p.2-7

Bono, Aldo V

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

Handling and Pathology Reporting of Radical Prostatectomy Specimens

Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer

The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma

Histopathology reporting of prostate needle biopsies. 2005 update

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis

Gene expression profiling of renal cell carcinoma: a DNA macroarray analysis

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use

Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study

Maintenance Bacillus Calmette-Guerin for TaT1 bladder tumors is not associated with increased toxicity: Results from a european organisation for research and treatment of cancer genito-urinary group phase III trial

Surgical pathology examination of radical prostatectomy specimens. Updated protocol based on the Italian TAP study

Somatostatin receptor subtypes in hormone-refractory （castration-resistant） prostatic carcinoma

Overview of Current Treatment Strategies in Prostate Cancer

Suchergebnisse filtern